Skip to main content

Institutional filer profile

ARCH Venture Fund IX Overage L.P. Insider Trades

ARCH Venture Fund IX Overage L.P. has reported 1 open-market purchase on SEC Form 4 and is a net buyer of $24,960,152 across 2 companies. The most recent open-market transaction was reported on Nov 4, 2026. Source: SEC Form 4 filings.

Latest reported as Corporate insider of Lyell Immunopharma, Inc. (LYEL).

SEC-reported filing activity is provided for research purposes and is not investment advice.

Purchase filings
1
Reported companies
2
Net open-market value
$24,960,152
Latest transaction
Nov 4, 2026

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Nov 4, 2026Lyell Immunopharma, Inc. (LYEL)Corporate insiderOpen Market Purchase2,321,262$10.77$24,999,992
Jul 1, 2026Boundless Bio, Inc. (BOLD)Corporate insiderSale16,000$2.49$39,840

Common questions

ARCH Venture Fund IX Overage L.P. insider trading FAQ

Is ARCH Venture Fund IX Overage L.P. buying or selling stock?
Across all SEC Form 4 open-market filings on record, ARCH Venture Fund IX Overage L.P. is a net buyer of $24,960,152, with 1 open-market purchase reported. The latest transaction was reported on Nov 4, 2026.
Which companies does ARCH Venture Fund IX Overage L.P. report insider trades for?
ARCH Venture Fund IX Overage L.P. has reported open-market trades in Lyell Immunopharma, Inc. (LYEL), Boundless Bio, Inc. (BOLD). The latest SEC-reported relationship is Corporate insider of Lyell Immunopharma, Inc. (LYEL).
Where does ARCH Venture Fund IX Overage L.P.'s insider trading data come from?
Watch Insiders reads the SEC Form 4 filings submitted to EDGAR under filer CIK 1666307, and refreshes this page daily.